I'll jump right in. I'll be making some forward-looking statements during today's presentation, so please refer to our SEC filings for additional disclosure on the various risks that we face. As was just highlighted, I've now stepped into the CEO role about a year ago, and it's been a really exciting year for the company. It's been a transformative year for the company, and I'd say it's been underscored by a renewed sense of urgency and focus across all aspects of the business, a commitment to a simpler organization structure, which was also highlighted by some of the decisions we made earlier in the year to divest our embedded CDMO operation to Bora. That deal closed at the end of Q2, brought in $120 million. We're able to also right-size the operation to about now 140 employees. Previously, we were well into the 300 number.
We're definitely a leaner, meaner organization, very much committed to delivering value for our shareholders and for also delivering transformative medicines for the patients that we serve. You can see on the slide we have a broad base committed to next-generation antibody therapeutics with three core platforms. Much of that is leveraging homegrown technology, including our DART and TRIDENT platforms that enable multi-specific targeting. We also have a keen interest in ADCs, where we're leveraging best-of-breed technology that we've licensed through third- parties that have proprietary drug linker chemistries, four clinical stage programs, and soon to be five with another ADC that will be entering the clinic imminently. What's also important to highlight is we're not just a technology boutique.
We have had a history of really being able to navigate drug development and take things all the way with three assets from our early-stage portfolio that are now on the market and being sold. For all three of the assets listed here, we maintain some residual economic interest in those programs. Over this last year, we've been phenomenally productive with BD in partnering. We've brought in over $300 million into the company, so we have a very strong financial footing with cash runway through the end of 2028. The pro forma cash balance that we highlighted on our last earnings call is about $327 million.
That gives effect to also the Bora consideration for the sale of the manufacturing facility, some milestone that we received from Sanofi related to the TZIELD asset, as well as a partnership milestone that was paid by Gilead, which is a really important corporate collaborator for the company. You can see on our pipeline slide eight separate assets that are listed here. Many of them we retain global rights, including all of our ADC portfolio listed as 026, 028, and 030. Two of those ADCs are first-in-class programs. That includes the ADAM9 program, which is called MGC028, and a third program, which is still an undisclosed target, where IND was filed actually a quarter ahead of schedule. It was cleared, and we're now going to be dosing patients very soon.
We have our dual checkpoint molecule, lorigerlimab, and then the T-cell engager portfolio, where Gilead has been a really strong partner here. First project was partnered in late 2022. About a year later, they came back. They wanted to expand with a second molecule, which is a TRIDENT-based construct, so that enables trivalent targeting for solid tumor applications. Last November, we added a third molecule into the mix here, so three active programs. What we also just highlighted recently in our earnings press release was a new molecule called MGD032. This is a next-gen T-cell engager that we think potentially addresses some of the challenges of conventional CD3-based targeting approaches, both better safety as well as potential extended durability, which is something we're very excited about, and that molecule is moving into IND-enabling studies. It is directed against an undisclosed target.
Just quickly, a little bit on some of these future assets. 026, this is a program we'll be presenting a clinical update at ESMO in late October. This is a program we're very excited about. Also, I think the broader industry has shown renewed interest in this target and has really started to appreciate the potential of B7-H3 targeting ADCs, which now have shown broad clinical validation in almost 15 different solid tumors. Small cell lung cancer is the one that has obviously garnered the most attention, but we think there's still a lot of room here to really build the franchise with our program. We have highlighted to date that we have an encouraging safety profile, including no ILD, which we attribute to some of the design features of our molecule.
It is an Fc- silenced design, which we think abrogates some of the nonspecific uptake of alveolar macrophages that potentially has driven some of the ILD liability for other groups. Head and neck cancer, we've now recently highlighted as an emerging lead indication, which we think is an area of high unmet need and very well matched with the profile of our molecule. I mentioned that B7-H3 is a very attractive target. Part of the appeal here is its multimodal kind of mechanisms. The fact that B7-H3 is expressed in the epithelial tumor, it's also expressed in the tumor-associated stromal component and the tumor vasculature.
We've also seen evidence that it's expressed in the myeloid-derived suppressor cell populations, which means if you can take out those cells, you may also potentially further improve the activity when combined with other complementary mechanisms like immune checkpoints, and we'll show you some data there, which we're really excited about. There are a number of other competitors in this space. We highlight on this slide four other programs that are very well-resourced. Daiichi and Merck, they actually have a PDUFA date in October for their small cell lung cancer efforts. Hansoh, GSK, MediLink, Roche, and Duality and BioNTech all working with Topo 1-based approaches. Each of these molecules has unique features. We highlight a few of the distinguishing factors. One is we are the only group here that has a site-specific conjugation approach, which enables a much more uniform DAR4 species. We have a silenced Fc- domain.
Within the Topo 1 class, not all Topo 1s are the same. Exatecan has shown in some preclinical work that has higher potency relative to deruxtecan, which is the operative payload with the Daiichi construct, about two to five-fold higher potency, actually better bystander killing effects, and less susceptibility to multi-drug resistance. So very good payload, very good linker. We also are very excited about the actual antibody construct that we have, which is a very efficient internalizer. We have completed the dose escalation of this study, which is on this slide. That happened late last year. We initiated expansion cohorts in these tumor-specific populations. Head and neck cancer is the one that's furthest along.
We did successfully clear the first stage of this Simon's two-stage design that was based on meeting a predefined ORR threshold and continue enrollment in a cohort for endometrial, melanoma, soft tissue sarcoma. Head and neck cancer, again, this is a space that a lot of attention in the last year or two, a lot of that's been driven by the successes of some of the EGFR bispecifics. You see here in terms of current standard of care, Pembro Plus or minus platinum-based chemo is the regimen of choice for frontline. Second line, there really is no clear preferred standard of care regimen. If you look at the efficacy of these second-line populations, it's pretty limited. Mid-teen response rates, in some cases depending on the subsets, it's even single-digit response rates. Beyond that, things are really purely relying on investigational therapies.
I mentioned earlier that ADC-B7-H3, given that it has an immune modulatory component as well as the potential to drive a cytotoxic that primes for antigen presentation and then sensitizes to immunotherapy. The notion of a combination regimen makes a lot of sense, especially for an indication like head and neck, where I mentioned Pembro is well entrenched. This is some preclinical data that highlights the really nice complementarity of these two mechanisms. On the left panel, you see a mirroring surrogate molecule for PD-1, and on the right-hand side, you see actually the additional benefit of dual blockade of both PD-1 and CTLA-4. 028, that is our next ADC pro first-in-class molecule targeting ADAM9, A disintegrin and metalloprotease 9. That is the target that plays a role in tumor genesis and cancer progression.
Very excited about the profile of this molecule. We completed all the IND enabling activities, including a GLP tox, which showed a 60 mg per kg HNSTD. The dose escalation is ongoing across a number of tumor types. You can see based on the IHC data, this target has very nice expression profile across a range of both GI cancers, lung, breast cancer, as well as others, and very potent killing in some of these animal model systems. 030, I mentioned that IND has been submitted and cleared, and we're doing a phase I start-up as we speak. This is a Topo 1-based molecule, although the tumors that we're addressing for this program are ones that are currently, I'd say, underserved by other competing ADC approaches, which makes this a really exciting molecule.
For competitive reasons, we decided not to disclose this molecule given that we are a first-in-class program with a Topo 1-based approach. Lorigerlimab, this is our dual molecule. You can see based on the cartoon schematic that it's a tetravalent structure. You have two binding domains for PD-1, two binding domains for CTLA-4. We think that actually enables some differentiation from some of the bivalent approaches like volrustomig. That's the one-by-one structure that's under development by AstraZeneca. We've had a lot of development experience with this molecule. I'd say a lot of lessons learned as well in terms of both target populations that we want to go after, as well as dosing and dose optimization. We have seen some early data in clear cell gyn cancer, which we're excited about, a 25% response rate.
That's a population that's typically more susceptible to immunotherapy and actually quite refractory to conventional platinum-based chemo approaches. The early experience with this molecule was predominantly at a 6 mg per kg dose every three weeks. We've decided to explore a lower dose of 3 mgs. That was based on some PK and PD modeling, which we believe we have complete receptor occupancy of PD-1 even at doses as low as 1 mg. We show good evidence of ICOS upregulation at these lower doses, and that's a marker for CTLA-4 blockade. Quite frankly, in the phase I, we had very strong activity with multiple resist responders at that 3 mg dose. That's what we're currently testing in our ongoing study. We have done some benchmarking work against volrustomig. That's the one-by-one structure.
Given that it has only monovalent engagement of PD-1, it really is not able to recapitulate the efficient PD-1 blockade of a typical PD-1 antibody, whereas our agent can. That's what's highlighted on the left panel. What's also highlighted on the right panel is the ability to preferentially target double positive TILs that have both PD-1 and CTLA-4 expression, and also localize the effect to those population and potentially have a much better systemic tox profile relative to just a combination of a PD-1 antibody and a CTLA-4 antibody. Clear cell, kind of the competitive positioning here, is a subset of that ovarian cancer population, although we're not needing to restrict further on target expression levels. Whereas in the high-grade serous population, groups like AbbVie with mirvetuximab are focusing only on a 30% subset based on folate receptor targeting.
We're looking at 100% of that clear cell population, which is a tumor that actually has very high unmet need. I mentioned it's typically refractory to chemo-based approaches. Platinum therapy is demonstrably ineffective in this population, so it's still an area of high unmet need. This is just a schematic on the design of the study, which I mentioned we're now adding an additional cohort to look at that lower 3-mg dose that's actively enrolling. We hope to have that enrolled and additional data reported out in 2027 on this program. 024 is our last program, which I'll just quickly highlight. This is a CD123 targeting program with a CD3 arm as well. CD123 is a leukemic stem cell target broadly expressed in both AML and MDS. We're completing the phase I dose optimization.
This is subject to a Gilead option agreement, and most of the disclosure at this point is really guided by them at this point. What I had highlighted at the beginning is this is a very good partnership where now we've extended to three molecules, all are T-cell engager-based approaches, and moving forward. We'll have additional update on this program, as well as the emerging portfolio, including our newly christened MGD032 molecule, which is a novel approach that actually is not reliant on CD3-based targeting approach. So a very catalyst-rich year that we've just come through. A lot of important catalysts still coming up. Both 026 and 028 are slated to have clinical updates later this year. 026 will be presenting some of that data at ESMO. We are moving the 030 program into first human studies, and that was about a quarter ahead of the original schedule.
Lorigerlimab, additional work there around the dose refinement, which I mentioned, and we'll have more clinical updates at ESMO and then next year as we get additional data from the 3 mg cohort. Our research team has been phenomenally productive with about one new IND a year. So 030 was the most recent IND, which is our ADC program. The next emerging candidate is a novel T-cell engager. MacroGenics has been a very prolific deal maker, probably one of the most active deal makers in biotech. Every year for the last decade, we've done one, if not multiple, high-value collaborations. My expectation is that's going to continue going forward. You can see even in the last year, we've been pretty active with collaborations with Gilead, the divestiture of the Bora.
We did a royalty monetization transaction with Sagard Health on our ZYNYZ program, and I think there's still ample room for additional partnering. Quite frankly, the bar keeps going up as well as what we look for from our prospective partners. We have a very good financial position, no debt on the balance sheet, very good cash balance, which again, enables us to really execute on the plan and provide a cash runway that goes through the end of 2028. A quick summary of some of the financials and also highlighting that we have the ability to also continue to bring in non-dilutive funding. We have not done a traditional equity raise for probably over seven years now, so most of the money has been sourced from non-dilutive means. You can see Gilead, Sanofi, Incyte, TerSera.
These are our four partners, and we have some residual economics that may come out of those, which are highlighted here. Those are substantive economics. With that, I'll close, and I'm happy to take any questions from the room.